Will GoodRX Stock Bounce Back?
GoodRX (NASDAQ:GDRX) tracks prescription drug prices and its model was…
Sell
29
VXRT Quote, Financials, Valuation and Earnings
Last price:
$0.40
Seasonality move
:
-1.32%
Day range:
$0.36 - $0.42
52-week range:
$0.26 - $1.07
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
1.82x
P/B ratio:
1.99x
Volume:
946.7K
Avg. volume:
8.7M
1-year change:
-45.6%
Market cap:
$90.7M
Revenue:
$28.7M
EPS (TTM):
-$0.27
Analysts' Opinion
-
Consensus RatingVaxart has received a consensus rating of Buy. The company's average rating is a Buy based on 3 Buy ratings, 0 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $4.67, Vaxart has an estimated upside of 1074.6% from its current price of $0.40.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $2.00 representing 100% downside risk from its current price of $0.40.
Fair Value
-
According to the consensus of 3 analysts, Vaxart has 1074.6% upside to fair value with a price target of $4.67 per share.
VXRT vs. S&P 500
-
Over the past 5 trading days, Vaxart has overperformed the S&P 500 by 32.35% suggesting its relative strength compared to the major market average is strong at this time.
Share Buyback
-
Vaxart does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Vaxart has grown year-over-year revenues for 6 quarters straight. In the most recent quarter Vaxart reported revenues of $20.9M.
Earnings Growth
-
Vaxart earnings have been falling on a year-over-year basis for 1 quarter in a row. In the most recent quarter Vaxart reported earnings per share of -$0.07.
Enterprise value:
48.7M
EV / Invested capital:
--
Price / LTM sales:
1.82x
EV / EBIT:
--
EV / Revenue:
1.03x
PEG ratio (5yr expected):
--
EV / Free cash flow:
-1.45x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
--
Return On Assets:
-41.87%
Net Income Margin (TTM):
-122.63%
Return On Equity:
-94.14%
Return On Invested Capital:
-94.14%
Operating Margin:
-71.54%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-03-31 | 2024-03-31 | 2025-03-31 | 2024-03-31 | 2025-03-31 | |
| Income Statement | ||||||
| Revenue | -- | $9.3M | $47.4M | $2.2M | $20.9M | |
| Gross Profit | -- | -- | -- | -- | -- | |
| Operating Income | -$111.1M | -$81.8M | -$57.2M | -$24.1M | -$14.9M | |
| EBITDA | -$99.8M | -$70.7M | -$45.7M | -$21.4M | -$12.3M | |
| Diluted EPS | -$0.83 | -$0.53 | -$0.27 | -$0.14 | -$0.07 | |
| Period Ending | 2021-03-31 | 2022-03-31 | 2023-03-31 | 2024-03-31 | 2025-03-31 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $175.4M | $154.2M | $75.8M | $44.3M | $62.6M | |
| Total Assets | $205.9M | $200.4M | $129.9M | $88.7M | $158.6M | |
| Current Liabilities | $11.6M | $11M | $15.7M | $14.1M | $98.5M | |
| Total Liabilities | $29.6M | $34M | $40.1M | $33M | $112.9M | |
| Total Equity | $176.2M | $166.4M | $89.8M | $55.7M | $45.6M | |
| Total Debt | -- | -- | -- | -- | -- | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-03-31 | 2024-03-31 | 2025-03-31 | 2024-03-31 | 2025-03-31 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$94.1M | -$67.2M | -$33.2M | -$21.2M | -$9.6M | |
| Cash From Investing | $1.3M | $13.5M | -$3.1M | -$5M | $13.2M | |
| Cash From Financing | $17.8M | $32M | $38.2M | $18.2M | -$164K | |
| Free Cash Flow | -$103.6M | -$67.9M | -$33.7M | -$21.3M | -$9.7M | |
VXRT
Sector
Market Cap
$90.7M
$34.4M
Price % of 52-Week High
37.13%
48.88%
Dividend Yield
0%
0%
Shareholder Yield
-40.83%
-1.01%
1-Year Price Total Return
-45.6%
-37.36%
Beta (5-Year)
1.144
0.614
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Buy
Level
$0.37
200-day SMA
Sell
Level
$0.59
Bollinger Bands (100)
Sell
Level
0.36 - 0.54
Chaikin Money Flow
Buy
Level
5.2M
20-day SMA
Sell
Level
$0.46
Relative Strength Index (RSI14)
Sell
Level
45.55
ADX Line
Buy
Level
15.71
Williams %R
Neutral
Level
-51.6212
50-day SMA
Sell
Level
$0.46
MACD (12, 26)
Buy
Level
0.11
25-day Aroon Oscillator
Sell
Level
-64
On Balance Volume
Sell
Level
-12.7M
Financial Scores
Sell
Altman Z-Score
(Annual)
Level (-4.4218)
Sell
CA Score
(Annual)
Level (-2.8234)
--
Beneish M-Score
(Annual)
Level (--)
Buy
Momentum Score
Level (2)
Sell
Ohlson Score
Level (4.9025)
--
Piotroski F Score
(Annual)
Level (--)
--
Quality Ratio Score
Level (--)
Sell
Fundamental Score
Level (2)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Vaxart Inc is a clinical-stage biotechnology company. It focuses on the development of oral recombinant vaccines based on its Vector Adjuvant Antigen Standardized Technology to protect against a wide range of infectious diseases. The products under its tablet pipeline consist of the treatment of Coronavirus, Norovirus, Seasonal Influenza, RSV(respiratory syncytial virus), and HPV(Human papillomavirus) Therapeutic. It operates in a single segment, which is the discovery and development of oral recombinant protein vaccines. Geographically all the business activity functions through the region of the United States.
Stock Forecast FAQ
In the current month, VXRT has received 3 Buy ratings 0 Hold ratings, and 0 Sell ratings. The VXRT average analyst price target in the past 3 months is $4.67.
-
Where Will Vaxart Stock Be In 1 Year?
According to analysts, the consensus estimate is that Vaxart share price will rise to $4.67 per share over the next 12 months.
-
What Do Analysts Say About Vaxart?
Analysts are divided on their view about Vaxart share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Vaxart is a Sell and believe this share price will drop from its current level to $2.00.
-
What Is Vaxart's Price Target?
The price target for Vaxart over the next 1-year time period is forecast to be $4.67 according to 3 Wall Street analysts, 3 of them rate the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is VXRT A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Vaxart is a Buy. 3 of 3 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of VXRT?
You can purchase shares of Vaxart via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, tastytrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Vaxart shares.
-
What Is The Vaxart Share Price Today?
Vaxart was last trading at $0.40 per share. This represents the most recent stock quote for Vaxart. Yesterday, Vaxart closed at $0.40 per share.
-
How To Buy Vaxart Stock Online?
In order to purchase Vaxart stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Will FCX Benefit From Tariffs?
Freeport-McMoRan (NYSE:FCX) is among the world’s largest producers of copper…
Can Levi Stock Double?
Levi Strauss (NYSE:LEVI) is among the oldest clothing brands in…
Stock Ideas
Buy
70
Is NVDA Stock a Buy?
Market Cap: $4.2T
P/E Ratio: 58x
Buy
62
Is MSFT Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 43x
Sell
40
Is AAPL Stock a Buy?
Market Cap: $3.1T
P/E Ratio: 35x
Alerts
Buy
82
SBET alert for Jul 17
SharpLink Gaming [SBET] is down 2.6% over the past day.
Buy
89
EXOD alert for Jul 17
Exodus Movement [EXOD] is down 4.14% over the past day.
Buy
60
U alert for Jul 17
Unity Software [U] is up 7.51% over the past day.
